Our CEO and founder Ali Salanti will be delivering an invited talk alongside other European and global leaders innovating in the antibody drug conjugate (ADC) space at the 15th World ADC London conference, scheduled to take place in London between March 3rd and 6th .
Ali will share with the audience our recent progress in the development and path to clinical translation of our first of its kind ADC targeting oncofetal CS, as well as the first preliminary data from our first-in-human imaging trial. We are looking forward to meeting participants and discussing collaboration opportunities around our lead ADC and beyond.